UA72426C2 - Human mutant interleukin-6, dna molecule coding it, vector, host cell, and also a method for obtaining and use of mutant il-6 for treatment of diseases with which il-6 has a pathogenic influence - Google Patents

Human mutant interleukin-6, dna molecule coding it, vector, host cell, and also a method for obtaining and use of mutant il-6 for treatment of diseases with which il-6 has a pathogenic influence Download PDF

Info

Publication number
UA72426C2
UA72426C2 UA98115904A UA98115904A UA72426C2 UA 72426 C2 UA72426 C2 UA 72426C2 UA 98115904 A UA98115904 A UA 98115904A UA 98115904 A UA98115904 A UA 98115904A UA 72426 C2 UA72426 C2 UA 72426C2
Authority
UA
Ukraine
Prior art keywords
mutant
human
sequence
interleukin
fragment
Prior art date
Application number
UA98115904A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA72426C2 publication Critical patent/UA72426C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Amplifiers (AREA)
  • Compounds Of Unknown Constitution (AREA)
UA98115904A 1996-04-09 1996-09-04 Human mutant interleukin-6, dna molecule coding it, vector, host cell, and also a method for obtaining and use of mutant il-6 for treatment of diseases with which il-6 has a pathogenic influence UA72426C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002251355A CA2251355C (en) 1996-04-09 1996-04-09 Il-6 mutein
PCT/EP1996/001506 WO1997038103A1 (en) 1996-04-09 1996-04-09 Il-6 mutein
CN96180247A CN1131309C (zh) 1996-04-09 1996-04-09 白细胞介素－6突变蛋白

Publications (1)

Publication Number Publication Date
UA72426C2 true UA72426C2 (en) 2005-03-15

Family

ID=27170853

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98115904A UA72426C2 (en) 1996-04-09 1996-09-04 Human mutant interleukin-6, dna molecule coding it, vector, host cell, and also a method for obtaining and use of mutant il-6 for treatment of diseases with which il-6 has a pathogenic influence

Country Status (18)

Country Link
US (1) US6280975B1 (de)
EP (1) EP0907737B1 (de)
JP (1) JP4189866B2 (de)
CN (1) CN1131309C (de)
AT (1) ATE291087T1 (de)
AU (1) AU728267B2 (de)
BR (1) BR9708648B1 (de)
CA (1) CA2251355C (de)
DE (1) DE69634497T2 (de)
DK (1) DK0907737T3 (de)
EA (1) EA000852B1 (de)
ES (1) ES2238690T3 (de)
FI (1) FI982198A7 (de)
IL (1) IL126484A0 (de)
NO (1) NO322479B1 (de)
PT (1) PT907737E (de)
UA (1) UA72426C2 (de)
WO (2) WO1997038103A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374159C (zh) 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
KR20060119412A (ko) * 2005-05-20 2006-11-24 아주대학교산학협력단 ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
US8522915B2 (en) * 2007-12-19 2013-09-03 Westerngeco L.L.C. Method and system for selecting parameters of a seismic source array
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途

Also Published As

Publication number Publication date
NO984697D0 (no) 1998-10-08
EP0907737B1 (de) 2005-03-16
AU728267B2 (en) 2001-01-04
IL126484A0 (en) 1999-08-17
HK1019770A1 (en) 2000-02-25
DE69634497T2 (de) 2006-01-26
AU5686496A (en) 1997-10-29
FI982198L (fi) 1998-10-09
US6280975B1 (en) 2001-08-28
CA2251355A1 (en) 1997-10-16
FI982198A0 (fi) 1998-10-09
EA000852B1 (ru) 2000-06-26
WO1997038103A1 (en) 1997-10-16
CN1131309C (zh) 2003-12-17
NO984697L (no) 1998-10-08
JP2000508164A (ja) 2000-07-04
EP0907737A1 (de) 1999-04-14
ATE291087T1 (de) 2005-04-15
ES2238690T3 (es) 2005-09-01
BR9708648A (pt) 1999-08-03
WO1997038104A1 (en) 1997-10-16
BR9708648B1 (pt) 2011-02-08
DK0907737T3 (da) 2005-06-27
FI982198A7 (fi) 1998-10-09
EA199800914A1 (ru) 1999-04-29
DE69634497D1 (de) 2005-04-21
PT907737E (pt) 2005-05-31
CN1216063A (zh) 1999-05-05
JP4189866B2 (ja) 2008-12-03
NO322479B1 (no) 2006-10-09
CA2251355C (en) 2009-06-09

Similar Documents

Publication Publication Date Title
Wuyts et al. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin‐8, granulocyte chemotactic protein‐2 and epithelial‐cell‐derived neutrophil attractant‐78
Van Damme et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.
EP1553182B1 (de) Regulierte Gene und ihre Verwendungen
EP1097173B1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
US5733730A (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
CN101157729A (zh) 一种肿瘤坏死因子相关凋亡配体变体及其应用
Qian et al. Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor beta on endothelial cells.
Kume et al. Probability that the commitment of murine erythroleukemia cell differentiation is determined by the c-myc level
CN102863537A (zh) 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
US20090092581A1 (en) Interferons of rhesus and cynomolgus origin and uses thereof
Lowe et al. Chimeric proteins define variable and essential regions of Ha-ras-encoded protein.
ZA200401001B (en) Bv8 nucleic acids and polypeptides with mitogenic activity.
UA72426C2 (en) Human mutant interleukin-6, dna molecule coding it, vector, host cell, and also a method for obtaining and use of mutant il-6 for treatment of diseases with which il-6 has a pathogenic influence
WO1992003479A1 (en) Replication initiator protein complex and methods of use thereof
CN112062854A (zh) 用于治疗肠癌的双特异性融合蛋白抗体及其应用
CN117715648A (zh) 靶向uPAR的抗原识别受体和其用途
Hughes et al. Heterodimerization with c-Fos is not required for cell transformation of chicken embryo fibroblasts by Jun
CN102382850A (zh) 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
CN101891824B (zh) 一种血管靶向可溶性融合蛋白TrxHis-hDll1-RGD
US6929791B2 (en) Peptides of IL-2 and derivatives thereof
Van Damme et al. IDENTIFICATION OF THE HUMAN 26-kD PROTEIN, INTERFERON 02 (IFN-N2), AS AB CELL HYBRIDOMA/PLASMACYTOMA GROWTH FACTOR INDUCED BY INTERLEUKIN 1 AND TUMOR NECROSIS FACTOR
US20070048302A1 (en) Peptides of IL-2
Cusi et al. Harlequin granulocyte-colony stimulating factor interleukin 6 molecules with bifunctional and antagonistic activities
Baier et al. Interleukin-16 for the gene therapy of HIV infection
ROBERTS Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor f3 on endothelial cells